Originally formed in 2008 to exploit the macrocyclic Cyclotide plant microprotein family as a therapeutic or delivery scaffold using phage display libraries.
Cyclogenix Technology expanded into:
Fully Human phage scFv antibody libraries
Large Cyclotide scaffold & VNAR single domain libraries
Filings on half-life extension IP, specific oral availability/BBB transfer sequences
More than 15 years experience in innovative protein engineering, and drug discovery display technologies e.g. invented CIS display at Isogenica.
Previously at Scotgen Biopharm, RRS, Haptogen and Isogenica.